We are live on ! Find out more
ALXA

Alexza Pharmaceuticals Inc
ALXA

Delisted

ALXA was delisted on the 16th of June, 2016.

Back to rankings

45 hedge funds and large institutions have $29.6M invested in Alexza Pharmaceuticals Inc in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

982% more call options, than puts

Call options by funds: $5.37M | Put options by funds: $496K

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

10% more funds holding

Funds holding: 41 → 45 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less capital invested

Capital invested by funds: $30.7M → $29.6M (-$1.09M)

Holders
45
Holders Change
+4
Holders Change %
+9.76%
% of All Funds
1.3%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
19
Reduced
11
Closed
2
Calls
$5.37M
Puts
$496K
Net Calls
+$4.87M
Net Calls Change
-$803K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$1.14M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$159K
3
VKH
Virtu KCG Holdings
New York
+$134K
4
Millennium Management
Millennium Management
New York
+$113K
5
CLOS
Compagnie Lombard Odier SCmA
Switzerland
+$82K

Top Sellers

Rank Fund Capital Flow
1
VM
VHCP Management
New York
-$652K
2
Group One Trading
Group One Trading
Illinois
-$169K
3
KCM
Kennedy Capital Management
Missouri
-$133K
4
GPCM
Granite Point Capital Management
Massachusetts
-$78K
5
Goldman Sachs
Goldman Sachs
New York
-$57.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
DIA
26
Denver Investment Advisors
Colorado
$92K +$36.5K +7,122 +52%
U
27
UBS
Switzerland
$68K -$18.3K -3,564 -19%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$66K -$48.3K -9,426 -39%
RCM
29
Rotella Capital Management
Washington
$59K +$68.4K +13,337 New
Citadel Advisors
30
Citadel Advisors
Florida
$58K +$51K +9,939 +306%
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$55K -$744 -145 -1%
Jacobs Levy Equity Management
32
Jacobs Levy Equity Management
New Jersey
$55K +$64.1K +12,500 New
SIM
33
Spark Investment Management
New York
$48K +$55.9K +10,900 New
BA
34
BlackRock Advisors
Delaware
$34K +$16.2K +3,158 +70%
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$21K +$10.8K +2,100 +76%
Citigroup
36
Citigroup
New York
$8K +$8.31K +1,620 +810%
TRCT
37
Tower Research Capital (TRC)
New York
$3K +$144 +28 +5%
AWM
38
Avior Wealth Management
Nebraska
$3K +$3.92K +765 New
SA
39
SRH Advisors
Kansas
$2K – – –
Creative Planning
40
Creative Planning
Kansas
$1K – – –
AllianceBernstein
41
AllianceBernstein
Tennessee
$1K +$15 +3 +1%
Manulife (Manufacturers Life Insurance)
42
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3 +$1.74K +340 +107%
GPCM
43
Granite Point Capital Management
Massachusetts
– -$78K -16,574 Closed
Wells Fargo
44
Wells Fargo
California
– -$103 -20 -33%
Nomura Holdings
45
Nomura Holdings
Japan
– +$26 +5 New
1
2

ALXA Hedge Fund Activity: Q1 2014 in Review

45 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Alexza Pharmaceuticals Inc (ALXA) for Q1 2014, worth a combined $29.6M — down 3.5% from $30.7M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ALXA positions and 2 closed out — a net gain of 4 holders — while 19 added to existing stakes and 11 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $1.14M. The largest seller was VHCP Management, cutting an estimated $652K.

  • 45 institutional investors held Alexza Pharmaceuticals Inc (ALXA) as of Q1 2014, up from 41 in Q4 2013.
  • Funds reported $29.6M of Alexza Pharmaceuticals Inc stock for Q1 2014, down 3.5% quarter-over-quarter.
  • 6 funds opened new Alexza Pharmaceuticals Inc positions in Q1 2014 and 2 closed out, a net change of +4 holders.
  • The largest Alexza Pharmaceuticals Inc buyer in Q1 2014 was Morgan Stanley, an estimated $1.14M added.
  • The largest Alexza Pharmaceuticals Inc seller in Q1 2014 was VHCP Management, an estimated $652K sold.

Based on aggregated 13F filings for Q1 2014.